Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown ...

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis. Welcome to this Contemporary Pediatrics poll. Take a look ...

On June 9, 2025, the FDA approved Merck's monoclonal antibody clesrovimab (Enflonsia) to protect infants from respiratory syncytial virus (RSV) disease during their first RSV season, according to a ...

Colleen Sloan, PA-C, RDN, shares some practical tips for providers and caregivers to help keep children hydrated during the summer. We know hydration matters—but in the heat of summer, it matters even ...

The case: A healthy 12-month-old girl presented with one small skin lesion over the right heel (Figure 1) for one month.On examination, her right lateral heel showed a round white pearl like hard tiny ...

The FDA has approved an expanded pediatric indication for the SONU Band (SoundHealth) for at-home treatment of moderate-to-severe nasal congestion because of allergic and non-allergic rhinitis in ...

Invasive Staphylococcus aureus infections remain a major cause of illness and death in neonatal intensive care units (NICUs), particularly among very low birth weight (VLBW) infants, according to a ...

Though the decision will not meet the June 17, 2025, target date, the federal agency anticipates a decision within approximately 4 weeks. The FDA will not meet a prescription drug user fee act (PDUFA) ...

Take a quick look at everything you may have missed last month, including the latest FDA updates, top stories, and exclusive interviews. May 2025 brought a series of critical developments that ...

The June 9, 2025, FDA approval of clesrovimab (Enflonsia; Merck) marked another advancement for the prevention of respiratory syncytial virus (RSV) disease in infants, especially during their first ...

Among children aged 1 to 11 years, new data for Valneva's chikungunya vaccine, IXCHIQ, revealed antibody persistence and safety for up to 6 months for the single-shot vaccine in both half- and ...

Despite decades of scientific progress, invasive Staphylococcus aureus infections remain a persistent and deadly threat to infants in neonatal intensive care units (NICUs)—especially those born ...